FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kent Osborne

Research Profile

Disorders

Chemicals & Drugs

Procedures

Physiology

Living Beings

Concepts & Ideas

Disease-Free Survival

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Mothaffar F Rimawi; Angel A Rodriguez; Rachel Schiff; Tao Wang; Andres Forero; Matthew P Goetz; Carolina Gutierrez; Susan G Hilsenbeck; Ingrid A Mayer; Rita Nanda; C Kent Osborne; Anne C Pavlick; Jenny C Chang
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006.
Luca Malorni; C Kent Osborne; M F Rimawi; P B Shetty; C De Angelis; Sabino De Placido; Richard M Elledge; Susan G Hilsenbeck; Grazia Arpino
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Albert C Chen; Chad J Creighton; M Carolina Gutierrez; Catherine Huang; Sara Lopez-Tarruella; Suleiman Massarweh; Ilenia Migliaccio; C Kent Osborne; Mothaffar Rimawi; Surinder K Batra; Yen-Chao Wang; Rachel Schiff
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kent Osborne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mothaffar F Rimawi; Angel A Rodriguez; Rachel Schiff; Tao Wang; Andres Forero; Matthew P Goetz; Carolina Gutierrez; Susan G Hilsenbeck; Ingrid A Mayer; Rita Nanda; C Kent Osborne; Anne C Pavlick; Jenny C Chang
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(14):1726-31.
2012: Luca Malorni; C Kent Osborne; M F Rimawi; P B Shetty; C De Angelis; Sabino De Placido; Richard M Elledge; Susan G Hilsenbeck; Grazia Arpino
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Breast cancer research and treatment 2012;136(3):795-804.
2012: Albert C Chen; Chad J Creighton; M Carolina Gutierrez; Catherine Huang; Sara Lopez-Tarruella; Suleiman Massarweh; Ilenia Migliaccio; C Kent Osborne; Mothaffar Rimawi; Surinder K Batra; Yen-Chao Wang; Rachel Schiff
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Breast cancer research and treatment 2012;134(2):583-93.
2012: Mothaffar F Rimawi; C Kent Osborne
Breast Cancer: Blocking both driver and escape pathways improves outcomes.
Nature reviews. Clinical oncology 2012;9(3):133-4.
2012: Jessica D Kessler; Mamie Z Li; Anthony C Liang; Ji Luo; Kristen L Meerbrey; C Kent Osborne; Mitchell Rao; Rachel Schiff; Michael R Schlabach; Earlene M Schmitt; Chad A Shaw; Samuel O Skinner; Nicole L Solimini; Tingting Sun; Ronald J Bernardi; Chad J Creighton; Rocio Dominguez-Vidana; Stephen J Elledge; Ido Golding; Zachary Conrad Hartman; Susan G Hilsenbeck; Tiffany Hsu; Kristopher T Kahle; Qikai Xu; Bing Yu; Peng Yu; Thomas F Westbrook
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Science (New York, N.Y.) 2012;335(6066):348-53.
2011: Mario Giuliano; C Kent Osborne; Rachel Schifp; Meghana V Trivedi
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Breast (Edinburgh, Scotland) 2011;20 Suppl 3():S42-9.
2011: Stefan Glück; Carlos L Arteaga; C Kent Osborne
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5559-61.
2011: Mothaffar F Rimawi; Lisa Wiechmann; Yen-Chao Wang; Catherine Huang; Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Susan G Hilsenbeck; Grazia Arpino; Suleiman Massarweh; Robin Ward; Robert Soliz; C Kent Osborne; Rachel Schiff
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(6):1351-61.
2011: Bhuvanesh Dave; Ilenia Migliaccio; M Carolina Gutierrez; Meng-Fen Wu; Gary C Chamness; Helen Wong; Archana Narasanna; Anindita Chakrabarty; Susan G Hilsenbeck; Jian Huang; Mothaffar Rimawi; Rachel Schiff; Carlos Arteaga; C Kent Osborne; Jenny C Chang
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(2):166-73.
2011: Yen-Chao Wang; Robin M Ward; Maria F Botero; Gary C Chamness; Xiaoyong Fu; Ryan Gillihan; Jun Guo; Nuala A Healy; Susan G Hilsenbeck; Gladys Morrison; C Kent Osborne; Gail Lewis Phillips; Mothaffar F Rimawi; Rachel Schiff
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Breast cancer research : BCR 2011;13(6):R121.
2011: Catherine Huang; C Kent Osborne; Catherine C Park; Mothaffar F Rimawi; Mina J Bissell; Susan G Hilsenbeck; Jiang Shou; Yen-Chao Wang; Robin Ward; Rachel Schiff
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Breast cancer research : BCR 2011;13(4):R84.
2011: C Kent Osborne; Rachel Schiff
Mechanisms of endocrine resistance in breast cancer.
Annual review of medicine 2011;62():233-47.
2010: Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Luca Malorni; Syed K Mohsin; D Craig Allred; Susan G Hilsenbeck; C Kent Osborne; Heidi Weiss; Adrian V Lee
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
Breast cancer research and treatment 2010;123(3):651-60.
2010: A A Rodriguez; Andreas Makris; Meng-Fen Wu; Mothaffar Rimawi; A Froehlich; B Dave; Susan G Hilsenbeck; Gary C Chamness; Michael Lewis; L E Dobrolecki; D Jain; S Sahoo; C Kent Osborne; Jenny C Chang
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Breast cancer research and treatment 2010;123(1):189-96.
2010: Stephanie Hammerich-Hille; Valerie J Bardout; Susan G Hilsenbeck; C Kent Osborne; Steffi Oesterreich
Low SAFB levels are associated with worse outcome in breast cancer patients.
Breast cancer research and treatment 2010;121(2):503-9.
2010: Mothaffar F Rimawi; Priya B Shetty; Heidi L Weiss; Rachel Schiff; C Kent Osborne; Gary C Chamness; Richard M Elledge
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.
Cancer 2010;116(5):1234-42.
2010: Chad J Creighton; Xiaoyong Fu; Bryan T Hennessy; Angelo J Casa; Yiqun Zhang; Ana Maria Gonzalez-Angulo; Ana Lluch; Joe Gray; Powel H Brown; Susan G Hilsenbeck; C Kent Osborne; Gordon B Mills; Adrian V Lee; Rachel Schiff
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Breast cancer research : BCR 2010;12(3):R40.
2010: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter M Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
The lancet oncology 2010;11(1):55-65.
2009: Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Lancet 2009;374(9707):2055-63.
2009: Dawn Hershman; Joseph M Unger; William E Barlow; Laura F Hutchins; Silvana Martino; C Kent Osborne; Robert B Livingston; Kathy S Albain
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2157-62.
2009: Tracy E Strecker; Qiang Shen; Yun Zhang; Jamal L Hill; Yuxin Li; Chunyu Wang; Hee-Tae Kim; Tona M Gilmer; Krystal R Sexton; Susan G Hilsenbeck; C Kent Osborne; Powel H Brown
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Journal of the National Cancer Institute 2009;101(2):107-13.
2008: Chad J Creighton; Suleiman Massarweh; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Jiang Shou; Luca Malorni; Rachel Schiff
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Cancer research 2008;68(18):7493-501.
2008: Chad J Creighton; Angelo Casa; Zawaunyka Lazard; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Adrian V Lee
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4078-85.
2008: X Li; Michael Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Journal of the National Cancer Institute 2008;100(9):672-9.
2008: Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Endocrine reviews 2008;29(2):217-33.
2008: Jenny C Chang; Andreas Makris; M Carolina Gutierrez; Susan G Hilsenbeck; James R Hackett; Jennie Jeong; Mei-Lan Liu; Joffre Baker; Kim Clark-Langone; Frederick L Baehner; Krsytal Sexton; Syed K Mohsin; Tara Gray; Laura Alvarez; Gary C Chamness; C Kent Osborne; Steven Shak
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Breast cancer research and treatment 2008;108(2):233-40.
2008: Suleiman Massarweh; C Kent Osborne; Chad J Creighton; Lanfang Qin; Anna Tsimelzon; Shixia Huang; Heidi Weiss; Mothaffar Rimawi; Rachel Schiff
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Cancer research 2008;68(3):826-33.
2007: Lois C Friedman; Catherine Romero; Richard M Elledge; Jenny Chang; Mamta Kalidas; Mario F Dulay; Garrett R Lynch; C Kent Osborne
Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancer.
Journal of behavioral medicine 2007;30(4):351-7.
2007: Grazia Arpino; Carolina Gutierrez; Heidi Weiss; Mothaffar Rimawi; Suleiman Massarweh; LAVINA BHARWANI; Sabino De Placido; C Kent Osborne; Rachel Schiff
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Journal of the National Cancer Institute 2007;99(9):694-705.
2007: Kishan J Pandya; Ping Hu; C Kent Osborne; Geoffrey Falkson; Douglass C Tormey
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
American journal of clinical oncology 2007;30(2):113-25.
2007: Hannah M Linden; Charles M Haskell; Stephanie J Green; C Kent Osborne; George W Sledge; Charles L Shapiro; James N Ingle; Danika Lew; Laura F Hutchins; Robert B Livingston; Silvana Martino
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):656-61.
2006: Li Hua Wang; Xiao Yi Yang; Xiaohu Zhang; Ping An; Han-Jong Kim; Jiaqiang Huang; Robert Clarke; C Kent Osborne; John K Inman; Ettore Appella; William L Farrar
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
Cancer cell 2006;10(6):487-99.
2006: Xiao-Jun Ma; Susan G Hilsenbeck; Wilson Wang; Li Ding; Dennis C Sgroi; Richard A Bender; C Kent Osborne; D Craig Allred; Mark G Erlander
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4611-9.
2006: Suleiman Massarweh; C Kent Osborne; Shou Jiang; Alan E Wakeling; Mothaffar Rimawi; Syed K Mohsin; Susan G Hilsenbeck; Rachel Schiff
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Cancer research 2006;66(16):8266-73.
2006: Jana Divisova; Isere Kuiatse; Zawaunyka Lazard; Heidi Weiss; Franzanne Vreeland; Darryl L Hadsell; Rachel Schiff; C Kent Osborne; Adrian V Lee
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Breast cancer research and treatment 2006;98(3):315-27.
2006: Susan G Hilsenbeck; C Kent Osborne
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1049s-1055s.
2006: Susan J Cleator; Anna Tsimelzon; Alan Ashworth; Mitch Dowsett; Timothy Dexter; Trevor Powles; Susan G Hilsenbeck; Helen Wong; C Kent Osborne; Peter O'Connell; Jenny C Chang
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
Breast cancer research and treatment 2006;95(3):229-33.
2006: Shiming Jiang; Rene Meyer; Kaiyan Kang; C Kent Osborne; Jiemin Wong; Steffi Oesterreich
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
Molecular endocrinology (Baltimore, Md.) 2006;20(2):311-20.
2006: Michelle D Martin; Susan G Hilsenbeck; Syed K Mohsin; Torsten A Hopp; Gary M Clark; C Kent Osborne; D Craig Allred; Peter O'Connell
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.
Breast cancer research and treatment 2006;95(1):7-12.
2005: Syed K Mohsin; D Craig Allred; C Kent Osborne; Anatolio Cruz; Pamela Otto; Helen K Chew; Gary M Clark; Richard M Elledge
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
Breast cancer research and treatment 2005;94(3):205-11.
2005: Yee-Lu Tham; L Fernando Gomez; Syed K Mohsin; M Carolina Gutierrez; Heidi Weiss; Susan G Hilsenbeck; Richard M Elledge; Gary C Chamness; C Kent Osborne; D Craig Allred; Jenny C Chang
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
Breast cancer research and treatment 2005;94(3):279-84.
2005: C Kent Osborne; Rachel Schiff; Grazia Arpino; Adrian Susan Lee; V G Hilsenbeck
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Breast (Edinburgh, Scotland) 2005;14(6):458-65.
2005: Laura F Hutchins; Stephanie J Green; Peter M Ravdin; Danika Lew; Silvana Martino; Martin D Abeloff; Alan P Lyss; Craig Allred; Saul E Rivkin; C Kent Osborne
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8313-21.
2005: Rachel Schiff; Suleiman Massarweh; Jiang Shou; LAVINA BHARWANI; Grazia Arpino; Mothaffar Rimawi; C Kent Osborne
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Cancer chemotherapy and pharmacology 2005;56 Suppl 1():10-20.
2005: Xiaojiang Cui; Rachel Schiff; Grazia Arpino; C Kent Osborne; Adrian V Lee
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7721-35.
2005: Grazia Arpino; Heidi Weiss; Adrian V Lee; Rachel Schiff; Sabino De Placido; C Kent Osborne; Richard M Elledge
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Journal of the National Cancer Institute 2005;97(17):1254-61.
2005: Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5973-82.
2005: Grazia Arpino; Heidi L Weiss; Gary M Clark; Susan G Hilsenbeck; C Kent Osborne
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4687-94.
2005: Anthony Howell; John Pippen; Richard M Elledge; Louis Mauriac; Ignace Vergote; Stephen E Jones; Steven E Come; C Kent Osborne; John F R Robertson
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Cancer 2005;104(2):236-9.
2005: Mitch Dowsett; Stephen Johnston; Lesley-Ann Martin; Janine Salter; Margaret Hills; Simone Detre; M Carolina Gutierrez; Syed K Mohsin; Jiang Shou; D Craig Allred; Rachel Schiff; C Kent Osborne; Ian Smith
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Endocrine-related cancer 2005;12 Suppl 1():S113-7.
2005: C Kent Osborne; Rachel Schiff
Aromatase inhibitors: future directions.
The Journal of steroid biochemistry and molecular biology 2005;95(1-5):183-7.
2005: Sanaa M Nabha; Selina Glaros; Meng Hong; Anne E Lykkesfeldt; Rachel Schiff; C Kent Osborne; Kaladhar B Reddy
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
Oncogene 2005;24(19):3166-76.
2005: M Carolina Gutierrez; Simone Detre; Stephen Johnston; Syed K Mohsin; Jiang Shou; D Craig Allred; Rachel Schiff; C Kent Osborne; Mitch Dowsett
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2469-76.
2005: Syed K Mohsin; Heidi L Weiss; M Carolina Gutierrez; Gary C Chamness; Rachel Schiff; Michael P DiGiovanna; Chun-Xia Wang; Susan G Hilsenbeck; C Kent Osborne; D Craig Allred; Richard M Elledge; Jenny C Chang
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2460-8.
2005: C Kent Osborne; Rachel Schiff
Estrogen-receptor biology: continuing progress and therapeutic implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(8):1616-22.
2005: Marc Lippman; Chris Benz; Arul M Chinnaiyan; David A Flockhart; Adrian Harris; Clifford Hudis; C Kent Osborne; Michael F Press; James M Rae; George W Sledge; Laura Van't Veer; Max S Wicha
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
Breast cancer research and treatment 2005;90(1):1-3.
2005: Jenny C Chang; Eric Wooten; Anna Tsimelzon; Susan G Hilsenbeck; M Carolina Gutierrez; Yee-Lu Tham; Mamta Kalidas; Richard M Elledge; Syed K Mohsin; C Kent Osborne; Gary C Chamness; D Craig Allred; Michael Lewis; Helen Wong; Peter O'Connell
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1169-77.
2005: Suzanne A W Fuqua; Yukun Cui; Adrian V Lee; C Kent Osborne; Kathryn B Horwitz
Insights into the role of progesterone receptors in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):931-2; author reply 932-3.
2005: C Kent Osborne; Jiang Shou; Suleiman Massarweh; Rachel Schiff
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):865s-70s.
2005: Steven E Come; Aman U Buzdar; James N Ingle; Carlos L Arteaga; Angela Brodie; GRaham Colditz; Stephen R D Johnston; Vessela N Kristensen; Per Eystein Lønning; Donald P McDonnell; C Kent Osborne; Jose Russo; Richard J Santen; Douglas Yee; Carol S Hart
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):861s-4s.
2005: Rachel Schiff; C Kent Osborne
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Breast cancer research : BCR 2005;7(5):205-11.
2005: Lori J Pierce; Laura F Hutchins; Stephanie R Green; Danika L Lew; Julie R Gralow; Robert B Livingston; C Kent Osborne; Kathy S Albain
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):24-9.
2004: Torsten A Hopp; Heidi L Weiss; Irma Parra; Yukun Cui; C Kent Osborne; Suzanne A W Fuqua
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7490-9.
2004: Grazia Arpino; Stephanie J Green; D Craig Allred; Dannika Lew; Silvana Martino; C Kent Osborne; Richard M Elledge
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5670-6.
2004: Jiang Shou; Suleiman Massarweh; C Kent Osborne; Alan E Wakeling; Simale Ali; Heidi Weiss; Rachel Schiff
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Journal of the National Cancer Institute 2004;96(12):926-35.
2004: Anthony Howell; John F R Robertson; Paul Abram; Mikhail R Lichinitser; Richard M Elledge; Emilio Bajetta; Toru Watanabe; Charles Morris; Alan Webster; Isaiah Dimery; C Kent Osborne
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1605-13.
2004: C Kent Osborne; Alan E Wakeling; R I Nicholson
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
British journal of cancer 2004;90 Suppl 1():S2-6.
2004: Anthony Howell; C Kent Osborne; Louis Mauriac
Spreading the word, but not too thinly.
Lancet 2004;363(9403):165-6.
2004: John F R Robertson; Bjørn Erikstein; C Kent Osborne; John Pippen; Steven E Come; Leroy M Parker; Stan Gertler; Mike P Harrison; David A Clarke
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Clinical pharmacokinetics 2004;43(8):529-38.
2004: Rachel Schiff; Suleiman Massarweh; Jiang Shou; LAVINA BHARWANI; Syed K Mohsin; C Kent Osborne
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):331S-6S.
2003: Chunhua Lu; Corey Speers; Yun Zhang; Xiaochun Xu; Jamal Hill; Emily Steinbis; Joseph Celestino; Qiang Shen; Heetae Kim; Susan G Hilsenbeck; Syed K Mohsin; Alan E Wakeling; C Kent Osborne; Powel H Brown
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Journal of the National Cancer Institute 2003;95(24):1825-33.
2003: C Kent Osborne; Rachel Schiff
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
Breast (Edinburgh, Scotland) 2003;12(6):362-7.
2003: C Kent Osborne; Carlos L Arteaga
Role of molecular and genetic markers in breast cancer treatment decisions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23 Suppl):285s-287s.
2003: Jenny C Chang; Eric Wooten; Anna Tsimelzon; Susan G Hilsenbeck; M Carolina Gutierrez; Richard M Elledge; Syed K Mohsin; C Kent Osborne; Gary C Chamness; D Craig Allred; Peter O'Connell
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Lancet 2003;362(9381):362-9.
2003: Ashby J Morrison; Rafael E Herrera; Ester Coronado Heinsohn; Rachel Schiff; C Kent Osborne
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Molecular endocrinology (Baltimore, Md.) 2003;17(8):1543-54.
2003: John F R Robertson; C Kent Osborne; Anthony Howell; Stephen E Jones; Louis Mauriac; Matthew Ellis; Ulrich R Kleeberg; Steven E Come; Ignace Vergote; Stan Gertler; Aman U Buzdar; Alan Webster; Charles Morris
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Cancer 2003;98(2):229-38.
2003: Martin S Tallman; Robert Gray; Nicholas J Robert; Charles F LeMaistre; C Kent Osborne; William P Vaughan; William J Gradishar; Thomas M Pisansky; John H Fetting; Elisabeth Paietta; Hillard M Lazarus
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
The New England journal of medicine 2003;349(1):17-26.
2003: Louis Mauriac; John Pippen; J Quaresma Albano; Stan Gertler; C Kent Osborne
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
European journal of cancer (Oxford, England : 1990) 2003;39(9):1228-33.
2003: Suzanne A W Fuqua; Rachel Schiff; Irma Parra; John T Moore; Syed K Mohsin; C Kent Osborne; Gary M Clark; D Craig Allred
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.
Cancer research 2003;63(10):2434-9.
2003: Valérie-Jeanne Bardou; Grazia Arpino; Richard M Elledge; C Kent Osborne; Gary M Clark
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1973-9.
2003: Ignace Vergote; John F R Robertson; Ulrich R Kleeberg; G Burton; C Kent Osborne; L Mauriac
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Breast cancer research and treatment 2003;79(2):207-11.
2003: Francisco J Esteva; John Glaspy; Said Baidas; Leslie R Laufman; Laura F Hutchins; Maura Dickler; Debu Tripathy; Roger Cohen; Angela DeMichele; Richard C Yocum; C Kent Osborne; Daniel F Hayes; Gabriel N Hortobagyi; Eric Winer; George D Demetri
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):999-1006.
2003: C Kent Osborne; Valerie Bardou; Torsten A Hopp; Gary C Chamness; Susan G Hilsenbeck; Suzanne A W Fuqua; Jiemin Wong; D Craig Allred; Gary M Clark; Rachel Schiff
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Journal of the National Cancer Institute 2003;95(5):353-61.
2003: Rachel Schiff; Suleiman Massarweh; Jiang Shou; C Kent Osborne
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):447S-54S.
2003: Steven E Come; Aman U Buzdar; Carlos L Arteaga; Angela Brodie; Nancy E Davidson; Mitch Dowsett; James N Ingle; Stephen R D Johnston; Adrian V Lee; C Kent Osborne; Kathleen I Pritchard; Victor G Vogel; Eric P Winer; Carol S Hart
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):443S-6S.
2003: Saul E Rivkin; Stephanie J Green; Danika Lew; John J Costanzi; John W Athens; C Kent Osborne; Clarence B Vaughn; Silvana Martino
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Cancer 2003;97(1):21-9.
2002: Huanzhang Lu; Yufeng Zhang; David D Roberts; C Kent Osborne; Nancy Smyth Templeton
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo.
Molecular therapy : the journal of the American Society of Gene Therapy 2002;6(6):783-92.
2002: Yongmin Liu; John H Ludes-Meyers; Yun Zhang; Debbie Munoz-Medellin; Heung Tae Kim; Chunhua Lu; Gouqing Ge; Rachel Schiff; Susan G Hilsenbeck; C Kent Osborne; Powel H Brown
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Oncogene 2002;21(50):7680-9.
2002: C Kent Osborne; John Pippen; Stephen E Jones; Leroy M Parker; M Ellis; Steven E Come; Stan Gertler; J T May; G Burton; Isaiah Dimery; Alan Webster; Charles Morris; Richard M Elledge; Aman U Buzdar
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3386-95.
2001: C Kent Osborne; Rachel Schiff; Suzanne A W Fuqua; Jiang Shou
Estrogen receptor: current understanding of its activation and modulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
2001: Aman U Buzdar; Steven E Come; Angela Brodie; M Ellis; P E Goss; James N Ingle; Stephen R D Johnston; Adrian V Lee; C Kent Osborne; V G Vogel; Carol S Hart
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
2001: Steffi Oesterreich; P Zhang; Rebecca L Guler; X Sun; Edward M Curran; Wade V Welshons; C Kent Osborne; Adrian V Lee
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
Cancer research 2001;61(15):5771-7.
2001: H H Zhao; Rafael E Herrera; EB Coronado-Heinsohn; M C Yang; John H Ludes-Meyers; K J Seybold-Tilson; Zafar Nawaz; D Yee; F G Barr; Sami Diab; Powel H Brown; Suzanne A W Fuqua; C Kent Osborne
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions.
The Journal of biological chemistry 2001;276(30):27907-12.
2001: M D Martin; Karl-Friedrich Fischbach; C Kent Osborne; Syed K Mohsin; D Craig Allred; Peter O'Connell
Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene.
Cancer research 2001;61(9):3578-80.
2001: Melanie T Hartsough; S E Clare; M Mair; Abdel G Elkahloun; Dennis C Sgroi; C Kent Osborne; G Clark; Patricia S Steeg
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Cancer research 2001;61(5):2320-7.
2001: Steffi Oesterreich; D C Allredl; Syed K Mohsin; Q Zhang; H Wong; Adrian V Lee; C Kent Osborne; Peter O'Connell
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.
British journal of cancer 2001;84(4):493-8.
2000: Rachel Schiff; P Reddy; M Ahotupa; EB Coronado-Heinsohn; M Grim; Susan G Hilsenbeck; R Lawrence; SM Deneke; Rafael E Herrera; Gary C Chamness; Suzanne A W Fuqua; Powel H Brown; C Kent Osborne
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
Journal of the National Cancer Institute 2000;92(23):1926-34.
2000: Steven M Townson; T Sullivan; Q Zhang; Gary M Clark; C Kent Osborne; Adrian V Lee; Steffi Oesterreich
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3788-96.
2000: C Kent Osborne; H Zhao; Suzanne A W Fuqua
Selective estrogen receptor modulators: structure, function, and clinical use.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3172-86.
2000: Anthony Howell; C Kent Osborne; Charles Morris; A E Wakeling
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
Cancer 2000;89(4):817-25.
2000: Richard M Elledge; S Green; R Pugh; D Craig Allred; Gary M Clark; J Hill; Peter M Ravdin; S Martino; C Kent Osborne
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
International journal of cancer. Journal international du cancer 2000;89(2):111-7.
2000: Steffi Oesterreich; Q Zhang; Torsten A Hopp; Suzanne A W Fuqua; M Michaelis; H H Zhao; James Davie; C Kent Osborne; Adrian V Lee
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Molecular endocrinology (Baltimore, Md.) 2000;14(3):369-81.
2000: J Chang; Trevor J Powles; DC Allred; SE Ashley; Andreas Makris; RK Gregory; C Kent Osborne; Mitch Dowsett
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):616-21.
1999: J Chang; Trevor J Powles; DC Allred; SE Ashley; G M Clark; Andreas Makris; Laura Assersohn; RK Gregory; C Kent Osborne; Mitch Dowsett
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3058-63.
1999: Peter O'Connell; Karl-Friedrich Fischbach; Susan G Hilsenbeck; Syed K Mohsin; Suzanne A W Fuqua; Gary M Clark; C Kent Osborne; D Craig Allred
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.
Journal of the National Cancer Institute 1999;91(16):1391-7.
1999: Ismail Jatoi; Susan G Hilsenbeck; Gary M Clark; C Kent Osborne
Significance of axillary lymph node metastasis in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2334-40.
1999: C Kent Osborne
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Endocrine-related cancer 1999;6(2):271-6.
1999: Jennet M Harvey; Gary M Clark; C Kent Osborne; D Craig Allred
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1474-81.
1999: Sami Diab; Gary M Clark; C Kent Osborne; A Libby; D Craig Allred; Richard M Elledge
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1442-8.
1999: Adrian V Lee; James G Jackson; Jennifer L Gooch; Susan G Hilsenbeck; EB Coronado-Heinsohn; C Kent Osborne; D Yee
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.
Molecular endocrinology (Baltimore, Md.) 1999;13(5):787-96.
1999: S Li; P L Chen; Thirugnana Subramanian; Govindaswamy Chinnadurai; Gail Tomlinson; C Kent Osborne; Zelton Sharp; W H Lee
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage.
The Journal of biological chemistry 1999;274(16):11334-8.
1999: Susan G Hilsenbeck; WE Friedrichs; Rachel Schiff; Peter O'Connell; Rhonda K Hansen; C Kent Osborne; Suzanne A W Fuqua
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
Journal of the National Cancer Institute 1999;91(5):453-9.
1998: C Kent Osborne
Tamoxifen in the treatment of breast cancer.
The New England journal of medicine 1998;339(22):1609-18.
1998: Edward G Mansour; R Gray; A H Shatila; Douglass C Tormey; M R Cooper; C Kent Osborne; Geoffrey Falkson
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3486-92.
1998: C E Geyer; S J Green; C M Moinpour; J O'Sullivan; D K Goodwin; V A Canfield; Frederick J Meyers; C Kent Osborne; S Martino
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Breast cancer research and treatment 1998;51(2):169-81.
1998: John H Fetting; R Gray; D L Fairclough; T J Smith; K A Margolin; M L Citron; M Grove-Conrad; David Cella; Kishan J Pandya; N Robert; I Craig Henderson; C Kent Osborne; MD Abeloff
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2382-91.
1998: Peter O'Connell; V Pekkel; Suzanne A W Fuqua; C Kent Osborne; Gary M Clark; D Craig Allred
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.
Journal of the National Cancer Institute 1998;90(9):697-703.
1998: Daniel R Ciocca; S Green; Richard M Elledge; Gary M Clark; R Pugh; Peter M Ravdin; D Lew; S Martino; C Kent Osborne
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1263-6.
1998: Geoffrey Falkson; Rebecca Gelman; Kishan J Pandya; C Kent Osborne; Douglass C Tormey; F J Cummings; G W Sledge; MD Abeloff
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1669-76.
1998: Sami Diab; Susan G Hilsenbeck; CA de Moor; Gary M Clark; C Kent Osborne; Peter M Ravdin; Richard M Elledge
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1655-60.
1998: C Kent Osborne; Richard M Elledge; P H Brown; Susan G Hilsenbeck
BRCA1 in clinical breast cancer.
Breast disease 1998;10(1-2):77-88.
1998: Melora Berardo; Richard M Elledge; C de Moor; Gary M Clark; C Kent Osborne; D Craig Allred
bcl-2 and apoptosis in lymph node positive breast carcinoma.
Cancer 1998;82(7):1296-302.
1998: RM Lavinsky; Kristen Jepsen; T Heinzel; Joseph Torchia; TM Mullen; R Schiff; A L Del-Rio; Mercedes Ricote; Sally D Ngo; J Gemsch; S G Hilsenbeck; C Kent Osborne; Christopher K Glass; Michael G Rosenfeld; David W Rose
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(6):2920-5.
1998: C W Taylor; S Green; W S Dalton; S Martino; D Rector; J N Ingle; N J Robert; G T Budd; J C Paradelo; R B Natale; James Bearden; James A Mailliard; C Kent Osborne
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):994-9.
1998: C Kent Osborne
Steroid hormone receptors in breast cancer management.
Breast cancer research and treatment 1998;51(3):227-38.
1998: Susan G Hilsenbeck; Peter M Ravdin; CA de Moor; Gary C Chamness; C Kent Osborne; Gary M Clark
Time-dependence of hazard ratios for prognostic factors in primary breast cancer.
Breast cancer research and treatment 1998;52(1-3):227-37.
1998: Richard M Elledge; S Green; Daniel R Ciocca; R Pugh; D Craig Allred; Gary M Clark; J Hill; Peter M Ravdin; J O'Sullivan; S Martino; C Kent Osborne
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):7-12.
1997: Gary M Clark; C Kent Osborne; D Levitt; F Wu; Nam W Kim
Telomerase activity and survival of patients with node-positive breast cancer.
Journal of the National Cancer Institute 1997;89(24):1874-81.
1997: Gary M Clark; D Craig Allred; Susan G Hilsenbeck; Gary C Chamness; C Kent Osborne; D Jones; W H Lee
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Cancer research 1997;57(24):5505-8.
1997: Stephen R D Johnston; B Lu; Mitch Dowsett; X Liang; M Kaufmann; Gary K Scott; C Kent Osborne; Christopher C Benz
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
Cancer research 1997;57(17):3723-7.
1997: C A Russell; Stephanie J Green; J O'Sullivan; H E Hynes; G T Budd; J E Congdon; Silvana Martino; C Kent Osborne
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2494-501.
1997: Richard M Elledge; C Kent Osborne
Oestrogen receptors and breast cancer.
BMJ (Clinical research ed.) 1997;314(7098):1843-4.
1997: C L Van den Berg; G N Cox; C A Stroh; Susan G Hilsenbeck; CN Weng; M J McDermott; D Pratt; C Kent Osborne; EB Coronado-Heinsohn; D Yee
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1108-13.
1997: Andreas Makris; DC Allred; Trevor J Powles; Mitch Dowsett; I N Fernando; PA Trott; SE Ashley; Michael G Ormerod; Jenny Titley; C Kent Osborne
Cytological evaluation of biological prognostic markers from primary breast carcinomas.
Breast cancer research and treatment 1997;44(1):65-74.
1997: Richard M Elledge; S Green; L Howes; Gary M Clark; Melora Berardo; D Craig Allred; R Pugh; Daniel R Ciocca; Peter M Ravdin; J O'Sullivan; S Rivkin; S Martino; C Kent Osborne
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1916-22.
1997: Andreas Makris; Trevor J Powles; Mitch Dowsett; C Kent Osborne; PA Trott; I N Fernando; SE Ashley; Michael G Ormerod; Jenny Titley; RK Gregory; DC Allred
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):593-600.
1997: J Grøndahl-Hansen; S G Hilsenbeck; I J Christensen; G M Clark; C Kent Osborne; Nils Brünner
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Breast cancer research and treatment 1997;43(2):153-63.
1996: Kathy S Albain; S R Green; A S Lichter; Laura F Hutchins; W C Wood; I C Henderson; J N Ingle; J O'Sullivan; C Kent Osborne; S Martino
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):3009-17.
1996: C Kent Osborne
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction.
Seminars in oncology 1996;23(4 Suppl 9):1.
1996: Steffi Oesterreich; Susan G Hilsenbeck; Daniel R Ciocca; D Craig Allred; Gary M Clark; Gary C Chamness; C Kent Osborne; Suzanne A W Fuqua
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1199-206.
1996: C Kent Osborne; E Coronado-Heinsohn
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
The cancer journal from Scientific American 1996;2(3):175-80.
1996: Robert I Nicholson; J M W Gee; S Bryant; A B Francis; Richard A McClelland; Janice M Knowlden; A E Wakeling; C Kent Osborne
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.
Annals of the New York Academy of Sciences 1996;784():325-35.
1996: Richard D Gelber; B F Cole; A Goldhirsch; C Rose; B Fisher; C Kent Osborne; F Boccardo; R Gray; N H Gordon; N O Bengtsson; P Sevelda
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Lancet 1996;347(9008):1066-71.
1996: R W Brown; C D Allred; G M Clark; C Kent Osborne; S G Hilsenbeck
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):585-92.
1996: S E Rivkin; S Green; J O'Sullivan; A B Cruz; M D Abeloff; W R Jewell; J J Costanzi; William B Farrar; C Kent Osborne
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):46-51.
1995: Yumay Chen; Chi-Fen Chen; Daniel Riley; D C Allred; Phang-Lang Chen; Daniel Von Hoff; C Kent Osborne; Wen-Hwa Lee
Aberrant subcellular localization of BRCA1 in breast cancer.
Science (New York, N.Y.) 1995;270(5237):789-91.
1995: J J Isola; Olli Kallioniemi; L W Chu; S A Fuqua; S G Hilsenbeck; C Kent Osborne; Frederic M Waldman
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer.
The American journal of pathology 1995;147(4):905-11.
1995: Richard M Elledge; R Gray; E Mansour; Y Yu; Gary M Clark; Peter M Ravdin; C Kent Osborne; K Gilchrist; Nancy E Davidson; N Robert
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
Journal of the National Cancer Institute 1995;87(16):1254-6.
1995: John A Katzenellenbogen; R E Coleman; R A Hawkins; K A Krohn; Steven M Larson; J Mendelsohn; C Kent Osborne; D Piwnica-Worms; R C Reba; B A Siegel
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):921-32.
1995: C Kent Osborne; E B Coronado-Heinsohn; Susan G Hilsenbeck; B L McCue; A E Wakeling; R A McClelland; DL Manning; R I Nicholson
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Journal of the National Cancer Institute 1995;87(10):746-50.
1995: E Rønne; Gunilla Høyer-Hansen; Nils Brünner; H Pedersen; F Rank; C Kent Osborne; G M Clark; K Danø; J Grøndahl-Hansen
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Breast cancer research and treatment 1995;33(3):199-207.
1994: Kaladhar B Reddy; D Yee; S G Hilsenbeck; R J Coffey; C Kent Osborne
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(12):1275-82.
1994: Carol J Fabian; Bruce F Kimler; R McKittrick; C H Park; F Lin; L Krishnan; W R Jewell; C Kent Osborne; S Martino; L F Hutchins
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.
Cancer research 1994;54(20):5357-62.
1994: S E Rivkin; S Green; B Metch; A B Cruz; M D Abeloff; W R Jewell; J J Costanzi; William B Farrar; J P Minton; C Kent Osborne
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2078-85.
1994: C Kent Osborne
Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee.
Cancer 1994;74(3 Suppl):1135-8.
1994: Richard M Elledge; Gary M Clark; Gary C Chamness; C Kent Osborne
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Journal of the National Cancer Institute 1994;86(9):705-12.
1994: Kim Margolin; S Green; C Kent Osborne; James Doroshow; Steven Akman; L A Leong; Robert J Morgan; James Raschko; George Somlo; L Hutchins
Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.
American journal of clinical oncology 1994;17(2):175-80.
1994: D Stein; J Wu; S A Fuqua; Chanland Roonprapunt; V Yajnik; P D'Eustachio; John Moskow; Arthur Buchberg; C Kent Osborne; Benjamin L Margolis
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.
The EMBO journal 1994;13(6):1331-40.
1994: Peter M Ravdin; A K Tandon; D Craig Allred; Gary M Clark; Suzanne A W Fuqua; S H Hilsenbeck; Gary C Chamness; C Kent Osborne
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):467-74.
1994: C Kent Osborne; M Jarman; R McCague; E B Coronado; S G Hilsenbeck; A E Wakeling
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.
Cancer chemotherapy and pharmacology 1994;34(2):89-95.
1994: C Kent Osborne; M C Sunderland; J A Neidhart; Peter M Ravdin; M D Abeloff
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):43-7.
1994: J O Atiba; S J Green; H E Hynes; C Kent Osborne; T P Miller; M Davidner
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1994;12(2):129-32.
1994: Charles F LeMaistre; C Meneghetti; L Howes; C Kent Osborne
Targeting the EGF receptor in breast cancer treatment.
Breast cancer research and treatment 1994;32(1):97-103.
1994: Suzanne A W Fuqua; Steffi Oesterreich; Susan G Hilsenbeck; Daniel Von Hoff; J Eckardt; C Kent Osborne
Heat shock proteins and drug resistance.
Breast cancer research and treatment 1994;32(1):67-71.
1994: Peter O'Connell; V Pekkel; Suzanne A W Fuqua; C Kent Osborne; D Craig Allred
Molecular genetic studies of early breast cancer evolution.
Breast cancer research and treatment 1994;32(1):5-12.
1994: C Kent Osborne; Suzanne A W Fuqua
Mechanisms of tamoxifen resistance.
Breast cancer research and treatment 1994;32(1):49-55.
1994: D Craig Allred; Peter O'Connell; Suzanne A W Fuqua; C Kent Osborne
Immunohistochemical studies of early breast cancer evolution.
Breast cancer research and treatment 1994;32(1):13-8.
1994: Gary M Clark; Susan G Hilsenbeck; Peter M Ravdin; Michele De Laurentiis; C Kent Osborne
Prognostic factors: rationale and methods of analysis and integration.
Breast cancer research and treatment 1994;32(1):105-12.
1994: C Kent Osborne; G C Chamness
Translational research in the San Antonio breast cancer SPORE.
Breast cancer research and treatment 1994;32(1):1-4.
1993: C Kent Osborne
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.
The Journal of steroid biochemistry and molecular biology 1993;47(1-6):83-9.
1993: Steffi Oesterreich; C N Weng; M Qiu; Susan G Hilsenbeck; C Kent Osborne; Suzanne A W Fuqua
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.
Cancer research 1993;53(19):4443-8.
1993: K A Hayden; Carol M Moinpour; B Metch; P Feigl; R M O'Bryan; S Green; C Kent Osborne
Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial.
Oncology nursing forum 1993;20(9):1415-9.
1993: S E Rivkin; S Green; B Metch; W R Jewell; J J Costanzi; S J Altman; J P Minton; R M O'Bryan; C Kent Osborne
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(9):1710-6.
1993: V J Wiebe; C Kent Osborne; S A Fuqua; Michael W DeGregorio
Tamoxifen resistance in breast cancer.
Critical reviews in oncology/hematology 1993;14(3):173-88.
1993: D Craig Allred; Gary M Clark; Richard M Elledge; Suzanne A W Fuqua; R W Brown; Gary C Chamness; C Kent Osborne; W L McGuire
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
Journal of the National Cancer Institute 1993;85(3):200-6.
1993: C A Encarnación; Daniel R Ciocca; W L McGuire; Gary M Clark; Suzanne A W Fuqua; C Kent Osborne
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
Breast cancer research and treatment 1993;26(3):237-46.
1992: D Craig Allred; Gary M Clark; R Molina; A K Tandon; S J Schnitt; K W Gilchrist; C Kent Osborne; D C Tormey; W L McGuire
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Human pathology 1992;23(9):974-9.
1992: Kaladhar B Reddy; G L Mangold; A K Tandon; Toshiyuki Yoneda; Gregory R Mundy; Asher Zilberstein; C Kent Osborne
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Cancer research 1992;52(13):3636-41.
1992: V J Wiebe; C Kent Osborne; W L McGuire; Michael W DeGregorio
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):990-4.
1992: Richard M Elledge; W L McGuire; C Kent Osborne
Prognostic factors in breast cancer.
Seminars in oncology 1992;19(3):244-53.
1992: C Kent Osborne
Prognostic factors for breast cancer: have they met their promise?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):679-82.
1992: D Craig Allred; Gary M Clark; A K Tandon; R Molina; D C Tormey; C Kent Osborne; K W Gilchrist; E G Mansour; M Abeloff; L Eudey
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):599-605.
1992: Gary M Clark; M C Mathieu; M A Owens; Lynn Dressler; L Eudey; D C Tormey; C Kent Osborne; K W Gilchrist; E G Mansour; M D Abeloff
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):428-32.
1992: C Kent Osborne; V J Wiebe; W L McGuire; Daniel R Ciocca; Michael W DeGregorio
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):304-10.
1992: Christopher C Benz; Gary K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H Michael Shepard; C Kent Osborne
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
Breast cancer research and treatment 1992;24(2):85-95.
1992: E G Mansour; L Eudey; D C Tormey; A H Shatila; C Kent Osborne; K W Gilchrist; M R Cooper; G Falkson
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Journal of the National Cancer Institute. Monographs 1992;(11):97-104.
1992: Lynn Dressler; L Eudey; R Gray; D C Tormey; W L McGuire; K W Gilchrist; Gary M Clark; C Kent Osborne; E G Mansour; M D Abeloff
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).
Journal of the National Cancer Institute. Monographs 1992;(11):167-72.
1992: C Kent Osborne; B A Blumenstein; E D Crawford; G R Weiss; R M Bukowski; N R Larrimer
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):477-8.
1992: K S Albain; S Green; M LeBlanc; S Rivkin; J O'Sullivan; C Kent Osborne
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Breast cancer research and treatment 1992;22(3):273-84.
1992: C Kent Osborne
Polypeptide growth factors: their potential value in the management of breast cancer patients.
Cancer treatment and research 1992;60():315-29.
1991: C Kent Osborne
Hematopoietic growth factors in breast cancer--overview.
Breast cancer research and treatment 1991;20 Suppl():S1-2.
1991: C Kent Osborne
Dose intensity as a therapeutic strategy in breast cancer.
Breast cancer research and treatment 1991;20 Suppl():S11-4.
1991: C Kent Osborne; E Coronado; D Craig Allred; V Wiebe; Michael W DeGregorio
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.
Journal of the National Cancer Institute 1991;83(20):1477-82.
1991: G Thomas Budd; S Green; Laurence H Baker; E P Hersh; J K Weick; C Kent Osborne
A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer.
Cancer 1991;68(8):1694-5.
1991: J D Cowan; J Neidhart; S McClure; C A Coltman; C Gumbart; S Martino; L F Hutchins; R L Stephens; C B Vaughan; C Kent Osborne
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1991;83(15):1077-84.
1991: M C Sunderland; C Kent Osborne
Tamoxifen in premenopausal patients with metastatic breast cancer: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1283-97.
1991: Kaladhar B Reddy; D Yee; C Kent Osborne
Rapid identification of transfected plasmid expression vectors in cells by PCR.
BioTechniques 1991;10(4):481-2, 484.
1991: Daniel Von Hoff; S J Green; J A Neidhart; C Fabian; T Budd; J F Boyd; C Kent Osborne
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):87-8.
1991: Carlos L Arteaga; C Kent Osborne
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.
Cancer treatment and research 1991;53():289-304.
1990: C Kent Osborne; David R Clemmons; Carlos L Arteaga
Regulation of breast cancer growth by insulin-like growth factors.
The Journal of steroid biochemistry and molecular biology 1990;37(6):805-9.
1990: David R Clemmons; Cecilia Camacho-Hubner; E Coronado; C Kent Osborne
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status.
Endocrinology 1990;127(6):2679-86.
1990: C Kent Osborne; B Blumenstein; E D Crawford; C A Coltman; A Y Smith; B W Lambuth; Robert A Chapman
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1675-82.
1990: C Kent Osborne; Carlos L Arteaga
Autocrine and paracrine growth regulation of breast cancer: clinical implications.
Breast cancer research and treatment 1990;15(1):3-11.
1989: D E Merkel; C Kent Osborne
Prognostic factors in breast cancer.
Hematology/oncology clinics of North America 1989;3(4):641-52.
1989: Carlos L Arteaga; C Kent Osborne
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
Cancer research 1989;49(22):6237-41.
1989: C Kent Osborne; E B Coronado; L J Kitten; C I Arteaga; Suzanne A W Fuqua; K Ramasharma; M Marshall; C H Li
Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor.
Molecular endocrinology (Baltimore, Md.) 1989;3(11):1701-9.
1989: Carlos L Arteaga; L J Kitten; E B Coronado; S Jacobs; F C Kull; D C Allred; C Kent Osborne
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.
The Journal of clinical investigation 1989;84(5):1418-23.
1989: W L McGuire; Patricia A. Johnson; Hyman Muss; C Kent Osborne
Megestrol acetate in breast cancer--a panel discussion.
Breast cancer research and treatment 1989;14(1):33-8.
1989: C Kent Osborne
DNA flow cytometry in early breast cancer: a step in the right direction.
Journal of the National Cancer Institute 1989;81(18):1344-5.
1989: S E Rivkin; S Green; B Metch; H Glucksberg; N Gad-el-Mawla; J J Constanzi; B Hoogstraten; J Athens; T Maloney; C Kent Osborne
Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1229-38.
1989: E Liu; G Santos; W M Lee; C Kent Osborne; C C Benz
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
Oncogene 1989;4(8):979-84.
1989: C Kent Osborne; J B Craig; K Klein; E D Crawford; J Turner
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer.
Investigational new drugs 1989;7(2-3):243-5.
1989: C Kent Osborne; L Kitten; Carlos L Arteaga
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(6):710-7.
1989: W L McGuire; M D Abeloff; B Fisher; J H Glick; I C Henderson; C Kent Osborne
Adjuvant therapy in node-negative breast cancer. A panel discussion.
Breast cancer research and treatment 1989;13(2):97-115.
1989: E G Mansour; R Gray; A H Shatila; C Kent Osborne; D C Tormey; K W Gilchrist; M R Cooper; G Falkson
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
The New England journal of medicine 1989;320(8):485-90.
1989: Robert T Dorr; J D Liddil; Daniel Von Hoff; M Soble; C Kent Osborne
Antitumor activity and murine pharmacokinetics of parenteral acronycine.
Cancer research 1989;49(2):340-4.
1989: D E Merkel; C Kent Osborne
Adjuvant treatment of node-negative breast cancer.
Texas medicine 1989;85(1):32-6.
1989: Michael W DeGregorio; E Coronado; C Kent Osborne
Tumor and serum tamoxifen concentrations in the athymic nude mouse.
Cancer chemotherapy and pharmacology 1989;23(2):68-70.
1989: C Kent Osborne
Cell proliferative indices and DNA content as prognostic factors in primary breast cancer.
Hormone research 1989;32 Suppl 1():238-41.
1989: W L McGuire; Kathleen M Foley; M H Levy; C Kent Osborne
Pain control in breast cancer. A panel discussion.
Breast cancer research and treatment 1989;13(1):5-15.
1989: N J Robert; W S Dalton; C Kent Osborne; M Abeloff
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
Hormone research 1989;32 Suppl 1():221-2.
1988: Carlos L Arteaga; E Coronado; C Kent Osborne
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer.
Molecular endocrinology (Baltimore, Md.) 1988;2(11):1064-9.
1988: W L McGuire; R B Dickson; C Kent Osborne; D Salomon
The role of growth factors in breast cancer. A panel discussion.
Breast cancer research and treatment 1988;12(2):159-66.
1988: Carlos L Arteaga; A R Hanauske; Gary M Clark; C Kent Osborne; P Hazarika; R L Pardue; F Tio; Daniel Von Hoff
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Cancer research 1988;48(17):5023-8.
1988: Carlos L Arteaga; A K Tandon; Daniel Von Hoff; C Kent Osborne
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Cancer research 1988;48(14):3898-904.
1988: C Kent Osborne; C R Ross; E B Coronado; Suzanne A W Fuqua; L J Kitten
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model.
Breast cancer research and treatment 1988;11(3):211-9.
1988: C Kent Osborne
Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer.
Cancer treatment and research 1988;39():111-29.
1987: Nils Brünner; C Kent Osborne; Mogens Spang-Thomsen
Endocrine therapy of human breast cancer grown in nude mice.
Breast cancer research and treatment 1987;10(3):229-42.
1987: G R Brown; R E Askew; H S Gallager; G N Hortobagyi; E D Montague; L E Neff; C Kent Osborne; G J Race; R J Salem; C M Townsend
Breast cancer. Breast Oncology Workgroup, Legislative Task Force on Cancer in Texas.
Texas medicine 1987;83(9 Pt 2):81-96.
1987: C Kent Osborne; E B Coronado; J P Robinson
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
European journal of cancer & clinical oncology 1987;23(8):1189-96.
1987: A R Hanauske; C Kent Osborne; Gary C Chamness; Gary M Clark; B J Forseth; J B Buchok; Carlos L Arteaga; Daniel Von Hoff
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(5):545-51.
1987: G M Clark; G W Sledge; C Kent Osborne; W L McGuire
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):55-61.
1987: Michael W DeGregorio; B J Wilbur; E Coronado; C Kent Osborne
Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.
Cancer chemotherapy and pharmacology 1987;20(4):316-8.
1987: W L McGuire; Marc Lippman; C Kent Osborne; E B Thompson
Resistance to endocrine therapy. A panel discussion.
Breast cancer research and treatment 1987;9(3):165-73.
1987: C Kent Osborne; K Hobbs; Jeffrey M. Trent
Biological differences among MCF-7 human breast cancer cell lines from different laboratories.
Breast cancer research and treatment 1987;9(2):111-21.
1986: K A Graham; Jeffrey M. Trent; C Kent Osborne; C M McGrath; M D Minden; R N Buick
The use of restriction fragment polymorphisms to identify the cell line MCF-7.
Breast cancer research and treatment 1986;8(1):29-34.
1986: C Kent Osborne; S E Rivkin; R W McDivitt; S Green; R L Stephens; J J Costanzi; R O'Bryan
Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
NCI monographs : a publication of the National Cancer Institute 1986;(1):71-4.
1986: C Kent Osborne; C A Coltman
Adjuvant chemotherapy.
CA: a cancer journal for clinicians 1986;36(1):59-60.
1985: S E Rivkin; W A Knight; R McDivitt; T Cruz; M Foulkes; C Kent Osborne; C J Fabian; J J Costanzi
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Journal of steroid biochemistry 1985;23(6B):1151-4.
1985: S E Rivkin; W A Knight; R McDivitt; T Cruz; M Foulkes; C Kent Osborne; C J Fabian; J J Costanzi
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
World journal of surgery 1985;9(5):723-7.
1985: S E Rivkin; H Glucksberg; M Foulkes; C Kent Osborne; W Tranum; N Gad-el-Mawla; J Constanzi
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.
World journal of surgery 1985;9(5):719-22.
1985: C Kent Osborne
Heterogeneity in hormone receptor status in primary and metastatic breast cancer.
Seminars in oncology 1985;12(3):317-26.
1985: C Kent Osborne; K Hobbs; G M Clark
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Cancer research 1985;45(2):584-90.
1985: J D Cowan; C Kent Osborne; J A Neidhart; Daniel Von Hoff; J J Constanzi; C B Vaughn
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Investigational new drugs 1985;3(2):149-52.
1985: C Kent Osborne; Daniel Von Hoff; K Mullins
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Breast cancer research and treatment 1985;6(3):229-35.
1984: C A Coltman; C Kent Osborne
Bisantrene, biological and clinical effects.
Cancer treatment reviews 1984;11(4):285-8.
1984: C Kent Osborne
Hormone receptors in the management of breast cancer.
Texas medicine 1984;80(11):30-2.
1984: G M Clark; C Kent Osborne; W L McGuire
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(10):1102-9.
1984: G E Gross; D H Boldt; C Kent Osborne
Perturbation by insulin of human breast cancer cell cycle kinetics.
Cancer research 1984;44(8):3570-5.
1984: C Kent Osborne; D H Boldt; P Estrada
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
Cancer research 1984;44(4):1433-9.
1984: C Kent Osborne; Daniel Von Hoff; J D Cowan; J Sandbach
Bisantrene, an active drug in patients with advanced breast cancer.
Cancer treatment reports 1984;68(2):357-60.
1983: C Kent Osborne; A Drelichman; Daniel Von Hoff; E D Crawford
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Cancer treatment reports 1983;67(12):1133-5.
1983: K J Ibbotson; S M D'Souza; K W Ng; C Kent Osborne; M Niall; T John Martin; G R Mundy
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy.
Science (New York, N.Y.) 1983;221(4617):1292-4.
1983: C Kent Osborne; D H Boldt; G M Clark; Jeffrey M. Trent
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.
Cancer research 1983;43(8):3583-5.
1983: A J Garvin; R M Simon; C Kent Osborne; J Merrill; R C Young; C W Berard
An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute.
Cancer 1983;52(3):393-8.
1983: D F Hull; G M Clark; C Kent Osborne; G C Chamness; W A Knight; W L McGuire
Multiple estrogen receptor assays in human breast cancer.
Cancer research 1983;43(1):413-6.
1983: J W Myers; Daniel Von Hoff; John Kuhn; C Kent Osborne; J F Sandbach; R Pocelinko
Anaphylactoid reactions associated with bisantrene infusions.
Investigational new drugs 1983;1(1):85-8.
1983: M E Monaco; C Kent Osborne; T J Bronzert; W R Kidwell; Marc Lippman
Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells.
Breast cancer research and treatment 1983;3(3):279-85.
1982: W L McGuire; C Kent Osborne; G M Clark; W A Knight
Steroid hormone receptors and carcinoma of the breast.
The American journal of physiology 1982;243(2):E99-102.
1982: S M Hubbard; B A Chabner; V T DeVita; R Simon; C W Berard; R B Jones; A J Garvin; George P Canellos; C Kent Osborne; R C Young
Histologic progression in non-Hodgkin's lymphoma.
Blood 1982;59(2):258-64.
1982: D L Elson; C Kent Osborne; R B Livingston; Daniel Von Hoff
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition.
Stem cells 1982;2(1):34-44.
1982: A J Suarez; D L Lamm; H M Radwin; M Sarosdy; G Clark; C Kent Osborne
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.
Cancer chemotherapy and pharmacology 1982;8(3):261-5.
1981: C Kent Osborne; B Hamilton; M Nover; J Ziegler
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells.
The Journal of clinical investigation 1981;67(4):943-51.
1981: Daniel Von Hoff; J Sandbach; C Kent Osborne; C Metelmann; G M Clark; M O'Brien
Potential and problems with growth of breast cancer in a human tumor cloning system.
Breast cancer research and treatment 1981;1(2):141-8.
1981: W A Knight; G M Clark; C Kent Osborne; W L McGuire
Adjuvant therapy for stage II, estrogen receptor negative breast cancer.
Breast cancer research and treatment 1981;1(2):131-4.
1981: C Kent Osborne
Combined chemo-hormonal therapy in breast cancer: a hypothesis.
Breast cancer research and treatment 1981;1(2):121-3.
1981: E R Fisher; C Kent Osborne; W L McGuire; C Redmond; W A Knight; B Fisher; G Bannayan; A Walder; E J Gregory; A Jacobsen; D M Queen; D E Bennett; H C Ford
Correlation of primary breast cancer histopathology and estrogen receptor content.
Breast cancer research and treatment 1981;1(1):37-41.
1981: C Kent Osborne; E Fisher; C Redmond; W A Knight; M G Yochmowitz; W L McGuire
Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis.
Advances in experimental medicine and biology 1981;138():377-85.
1980: C Kent Osborne; M G Yochmowitz; W A Knight; W L McGuire
The value of estrogen and progesterone receptors in the treatment of breast cancer.
Cancer 1980;46(12 Suppl):2884-8.
1980: C Kent Osborne; W A Knight; M G Yochmowitz; W L McGuire
Modern approaches to the treatment of breast cancer.
Blood 1980;56(5):745-52.
1980: W A Knight; C Kent Osborne; M G Yochmowitz; W L McGuire
Steroid hormone receptors in the management of human breast cancer.
Annals of clinical research 1980;12(5):202-7.
1980: C Kent Osborne; L Norton; R C Young; A J Garvin; R M Simon; C W Berard; S Hubbard; V T DeVita
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival.
Blood 1980;56(1):98-103.
1980: C Kent Osborne; B Hamilton; G Titus; R B Livingston
Epidermal growth factor stimulation of human breast cancer cells in culture.
Cancer research 1980;40(7):2361-6.
1980: W A Knight; C Kent Osborne; W L McGuire
Hormone receptors in primary and advanced breast cancer.
Clinics in endocrinology and metabolism 1980;9(2):361-8.
1979: S P Gaskill; W L McGuire; C Kent Osborne; Michael P Stern
Breast cancer mortality and diet in the United States.
Cancer research 1979;39(9):3628-37.
1979: C Kent Osborne; M E Monaco; C R Kahn; K Huff; D Bronzert; Marc Lippman
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture.
Cancer research 1979;39(7 Pt 1):2422-8.
1979: C Kent Osborne; W L McGuire
Therapy for cancer of the breast. Current status of steroid hormone receptors.
The Western journal of medicine 1979;130(5):401-7.
1979: C Kent Osborne; W L McGuire
The use of steroïd hormone receptors in the treatment of human breast cancer: a review.
Bulletin du cancer 1979;66(3):203-9.
1978: C Kent Osborne; W L McGuire
Current use of steroid hormone receptor assays in the treatment of breast cancer.
The Surgical clinics of North America 1978;58(4):777-88.
1978: C Kent Osborne; M E Monaco; Marc Lippman; C R Kahn
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture.
Cancer research 1978;38(1):94-102.
1977: M E Monaco; C Kent Osborne; Marc Lippman
Insulin stimulation of fatty acid synthesis in human breast cancer cells.
Journal of the National Cancer Institute 1977;58(6):1591-3.
1977: Marc Lippman; C Kent Osborne; R Knazek; N Young
In vitro model systems for the study of hormone-dependent human breast cancer.
The New England journal of medicine 1977;296(3):154-9.
1976: C Kent Osborne; G Bolan; M E Monaco; Marc Lippman
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin.
Proceedings of the National Academy of Sciences of the United States of America 1976;73(12):4536-40.
1976: P V Woolley; C Kent Osborne; J A Levi; P H Wiernik; George P Canellos
Extranodal presentation of non-Hodgkin's lymphomas in the testis.
Cancer 1976;38(2):1026-35.
1973: C Kent Osborne; R Carolla; D Jefferson; C E Mengel
Effect of methemoglobin on in vivo RBC lipid peroxidation.
Aerospace medicine 1973;44(1):63-7.